ERBB2 and metastatic neoplasm: Two of the three HER2 0 patients with a fatal outcome had a HER2 1+ lymph node deposit in one of their metastases, so that all but one of the fatal cases involved HER2-low protein expression levels in the primary or metastatic tumors or both.